Presenting at Cowen and Company Conference

RNS Number : 8089P
PureTech Health PLC
23 February 2016
 

 

PureTech Health plc

 

PureTech to present at the Cowen and Company 36th Annual Health Care Conference

 

Boston, Massachusetts, February 23, 2016 - PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, today announces that Daphne Zohar, PureTech's Chief Executive Officer, will be presenting at the Cowen and Company 36th Annual Health Care Conference in Boston, MA, being held on March 7-9, 2016.  

 

PureTech's presentation is scheduled for Monday 7 March 2016 at 4:40-5:10pm ET and will be followed by a breakout session from 5:15-5:45pm ET.

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company, developing innovative products that could improve the lives of billions of patients. PureTech has a pipeline of 12 operating companies, seven of which are "growth stage" with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech also has a pipeline of ten "concept phase" initiatives resulting from review of more than 650 ideas annually. PureTech is focused on areas including immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology; and infectious diseases, and has over 110 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 50 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. For more information, visit www.puretechhealth.com and connect with us on Twitter.

 

#  #  #

Enquiries:

 

PureTech

Stephen Muniz, Executive Vice President, Legal and Operations

+1 617 456 0042  

 

FTI Consulting (Communications adviser to PureTech)

Ben Atwell

Matthew Cole

+44 (0) 20 3727 1000

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUUVBRNKAUUAR
UK 100

Latest directors dealings